ZEN003694 for Squamous Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Do I need to stop my current medications for the trial?
The trial requires stopping medications that are strong inducers or inhibitors of CYP3A4 and substrates of CYP1A2 with a narrow therapeutic window at least 7 days before starting the study drug. If you're on these medications, you may need to stop them. The protocol does not specify other medications, so consult with the trial team for guidance.
What data supports the idea that ZEN003694 for Squamous Cell Lung Cancer (also known as: ZEN003694, ZEN-3694) is an effective treatment?
The available research does not provide specific data on the effectiveness of ZEN003694 for Squamous Cell Lung Cancer. Instead, it discusses the general progress in treatments for this type of cancer, including the development of new therapies and clinical trials. Other treatments, like immunotherapy and combinations of chemotherapy drugs, have shown promise in improving outcomes for patients with this condition.12345
What safety data exists for ZEN003694 in treating squamous cell lung cancer?
The provided research does not specifically mention safety data for ZEN003694 or ZEN-3694 in the treatment of squamous cell lung cancer. The articles focus on the safety and adverse events of other targeted therapies and immunotherapies for non-small cell lung cancer, including PD-1/PD-L1 inhibitors, but do not provide information on ZEN003694. Further specific studies or clinical trial data would be needed to determine the safety profile of ZEN003694.26789
Is the drug ZEN003694 a promising treatment for squamous cell lung cancer?
Yes, ZEN003694 is a promising drug for squamous cell lung cancer because recent research has identified new targets in the cancer's biology, leading to the development of targeted treatments like ZEN003694. These advancements offer new hope for patients by potentially improving survival rates and providing more effective treatment options.26101112
Research Team
Paul Paik
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults with advanced squamous cell lung cancer and NSD3 gene mutation can join this trial. They must have had prior chemotherapy and immunotherapy, be able to swallow capsules, and not be pregnant or breastfeeding. Stable brain metastases are okay. Participants need proper organ function, no recent heart attacks or surgeries, and cannot have HIV/HBV/HCV or other significant health issues.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ZEN003694 (BET inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
Chief Medical Officer since 2021
MD from Columbia University
Selwyn M. Vickers
Memorial Sloan Kettering Cancer Center
Chief Executive Officer since 2022
MD from Johns Hopkins University
Zenith Epigenetics
Industry Sponsor